Glucan preparation
DC CAFCFirst Claim
1. An underivatized, aqueous soluble β
- (1-3) glucan in a triple helix conformation having immunostimulating properties which does not stimulate or prime the production of interleukin-1 or tumor necrosis factor or both, in vitro.
15 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention relates to neutral soluble β-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel β-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the β-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo. Safe and efficacious preparations of neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1, TNF and leukotrienes) that can cause detrimental side effects, such as fever and inflammation.
98 Citations
35 Claims
-
1. An underivatized, aqueous soluble β
- (1-3) glucan in a triple helix conformation having immunostimulating properties which does not stimulate or prime the production of interleukin-1 or tumor necrosis factor or both, in vitro.
- View Dependent Claims (2, 3, 4)
-
5. An underivatized, aqueous soluble β
- (1-3) glucan in a triple helix conformation having immunostimulating properties which does not simulate or prime the production of interleukin-1 or tumor necrosis actor or both, in vitro and having an average molecular weight of from about 30,000 to about 300,000 daltons.
-
6. An underivatized, aqueous soluble yeast β
- (1-3) glucan in a triple helix conformation having immunostimulating properties which does not stimulate or prime the production of interleukin-1 or tumor necrosis factor or both, in vitro and having an average molecular weight of from about 30,000 to about 500,000 daltons.
- View Dependent Claims (7, 8)
-
9. A composition comprising an underivatized, aqueous soluble β
- (1-3) glucan in a triple helix conformation having immunostimulating properties, in a physiologically acceptable vehicle, wherein said glucan does not stimulate production of interleukin-1, tumor necrosis factor or both, in vitro.
- View Dependent Claims (10, 11, 12, 13)
-
14. A composition comprising an underivatized, aqueous soluble yeast β
- (1-3) glucan in a triple helix conformation having immunostimulating properties, in a physiologically acceptable vehicle, wherein said glucan does not stimulate production of interleukin-1, tumor necrosis factor or both, in vitro.
- View Dependent Claims (15, 16, 17, 18, 19, 20)
-
21. A process for producing an underivatized, aqueous soluble β
- (1-3) glucan in triple helix conformation having immunostimulating properties, comprising the steps of;
a) treating a suspension of a aqueous insoluble glucan with an acid to dissolve the acid-soluble portion of the glucan; b) treating the acid-soluble glucan with alkali to denature the native conformation of the soluble glucan; c) neutralizing the solution containing the denatured soluble glucan to re-anneal the soluble glucan; and d) purifying the re-annealed soluble glucan to obtain an underivatized, aqueous soluble β
(1-3) glucan in a triple helix conformation having immunostimulating properties. - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30, 31)
- (1-3) glucan in triple helix conformation having immunostimulating properties, comprising the steps of;
-
32. A process for producing an underivatized, aqueous soluble β
- (1-3) glucan in a triple helix conformation, comprising the steps of;
a) treating a suspension of aqueous insoluble glucan with an acid at a pH of from about 1 to about 5 and at a temperature of from about 20°
C. to about 120°
C. to dissolve the acid-soluble portion of the glucan;b) treating the acid-soluble glucan with alkali at a pH of from about 7 to about 14 and at a temperature of from about 4°
C. to about 121°
C. to denature the native conformation of the soluble glucan;c) neutralizing the solution containing the denatured soluble glucan to re-anneal the soluble glucan; and d) purifying the re-annealed soluble glucan to obtain an underivatized, aqueous soluble β
(1-3) glucan in a triple helix conformation. - View Dependent Claims (33, 34, 35)
- (1-3) glucan in a triple helix conformation, comprising the steps of;
Specification